ELI LILLY AND COMPANY

NYSE: LLY (Eli Lilly and Company)

Kemas kini terakhir: 10 jam lalu

999.84

-1.51 (-0.15%)

  • 1H -0.15%
  • 5H -0.37%
  • 1B -3.70%
  • 6B 32.36%
  • Tahun Ke Tarikh -7.45%
  • 1T 21.66%
  • 5T 380.51%
Penutupan Terdahulu 1,001.35
Buka 1,000.03
Jumlah Dagangan 1,031,358
Purata Dagangan (3B) 3,168,527
Modal Pasaran 894,875,598,848
Harga / Pendapatan (P/E TTM) 43.47
Harga / Pendapatan (P/E Ke hadapan) 29.24
Harga / Jualan (P/S) 13.80
Harga / Buku (P/B) 33.65
Julat 52 Minggu
623.78 (-37%) — 1,133.95 (13%)
Tarikh Pendapatan 30 Apr 2026
Hasil Dividen (DY TTM) 0.63%
Margin Keuntungan 22.67%
Margin Operasi (TTM) 42.49%
EPS Cair (TTM) 12.27
Pertumbuhan Hasil Suku Tahunan (YOY) 45.20%
Pertumbuhan Pendapatan Suku Tahunan (YOY) 23.00%
Jumlah Hutang/Ekuiti (D/E MRQ) 243.61%
Nisbah Semasa (MRQ) 1.37
Aliran Tunai Operasi (OCF TTM) 9.32 B
Aliran Tunai Bebas Leveraj (LFCF TTM) -1.82 B
Pulangan Atas Aset (ROA TTM) 16.45%
Pulangan Atas Ekuiti (ROE TTM) 77.28%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Drug Manufacturers - General (US) Menaik Bercampur
Drug Manufacturers - General (Global) Menaik Bercampur
Stok Eli Lilly and Company Menaik Menaik

AISkor Stockmoo

-0.1
Konsensus Penganalisis 3.0
Aktiviti Orang Dalam NA
Volatiliti Harga -0.5
Purata Bergerak Teknikal -2.5
Osilator Teknikal -0.5
Purata -0.13

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
LLY 895 B 0.63% 43.47 33.65
NVS 326 B 2.46% 23.58 6.66
NVO 163 B 3.00% 10.13 5.86
JNJ 587 B 2.14% 22.09 7.20
ABBV 407 B 0.71% 97.09 50.46
MRK 306 B 0.65% 17.01 5.65

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Sektor Healthcare
Industri Drug Manufacturers - General
Gaya Pelaburan Large Growth
% Dimiliki oleh Orang Dalam 0.16%
% Dimiliki oleh Institusi 83.96%

Pemilikan

Nama Tarikh Syer Dipegang
Lilly Endowment Inc 31 Dec 2025 92,190,516
Julat 52 Minggu
623.78 (-37%) — 1,133.95 (13%)
Julat Harga Sasaran
1,161.00 (-99%) — 1,350.00 (-99%)
Tinggi 1,350.00 (Barclays, 35.02%) Beli
Median 1,274.00 (27.42%)
Rendah 1,161.00 (Guggenheim, 16.12%) Beli
Purata 1,266.20 (26.64%)
Jumlah 10 Beli
Harga Purata @ Panggilan 1,037.80
Syarikat Tarikh Harga Sasaran Panggilan Harga @ Panggilan
RBC Capital 25 Feb 2026 1,250.00 (25.02%) Beli 1,028.83
Barclays 20 Feb 2026 1,350.00 (35.02%) Beli 1,009.52
Deutsche Bank 09 Feb 2026 1,285.00 (28.52%) Beli 1,044.67
Cantor Fitzgerald 05 Feb 2026 1,205.00 (20.52%) Beli 1,020.84
JP Morgan 05 Feb 2026 1,300.00 (30.02%) Beli 1,020.84
Morgan Stanley 05 Feb 2026 1,313.00 (31.32%) Beli 1,020.84
Wells Fargo 05 Feb 2026 1,280.00 (28.02%) Beli 1,020.84
Guggenheim 20 Jan 2026 1,161.00 (16.12%) Beli 1,041.29
UBS 07 Jan 2026 1,250.00 (25.02%) Beli 1,108.09
B of A Securities 15 Dec 2025 1,268.00 (26.82%) Beli 1,062.19

Tiada data dalam julat masa ini.

  • 3M
Tarikh Jenis Butiran
05 Mar 2026 CNBC Eli Lilly launches program to help boost employer coverage of obesity drugs in U.S.
24 Feb 2026 CNBC Eli Lilly launches new form of obesity drug Zepbound with a month’s worth of doses in one pen
24 Feb 2026 CNBC Novo Nordisk to slash GLP-1 list prices by up to 50% in U.S. to cut costs for insured patients
11 Feb 2026 CNBC Novo Nordisk faces a defining year in the obesity drug market. It’s off to a dramatic start
11 Feb 2026 CNBC Novo Nordisk CEO sees 15 million patient opportunity in Medicare coverage for obesity drugs
09 Feb 2026 CNBC FDA says Novo Nordisk's TV ad for obesity pill includes 'false or misleading' claims
09 Feb 2026 CNBC Novo Nordisk sues Hims & Hers over copycat versions of Wegovy drugs; Hims stock falls 18%
06 Feb 2026 CNBC White House launches direct-to-consumer drug site TrumpRx. Here's what to know
04 Feb 2026 CNBC Eli Lilly's GLP-1 growth is only getting started as Novo Nordisk braces for a decline in 2026
04 Feb 2026 CNBC Eli Lilly blows past quarterly estimates, posts strong outlook as Zepbound and Mounjaro sales soar
04 Feb 2026 Pengumuman Lilly reports fourth-quarter 2025 financial results and provides 2026 guidance
03 Feb 2026 CNBC Pfizer says obesity injection shows promise as monthly treatment in mid-stage trial
30 Jan 2026 CNBC Eli Lilly plans $3.5 billion manufacturing plant in Pennsylvania to make next-generation obesity injections
30 Jan 2026 Pengumuman Lilly selects Pennsylvania as home for its newest injectable medicine and device manufacturing facility
30 Jan 2026 CNBC Eli Lilly CEO says Medicare coverage of obesity drugs could 'change the game' for upcoming pill launch
23 Jan 2026 CNBC What obesity drugmakers see next in the market: More pills, easier access and drug combinations
21 Jan 2026 Pengumuman Lilly confirms date and conference call for fourth-quarter 2025 financial results announcement
20 Jan 2026 Pengumuman Lilly's sofetabart mipitecan receives U.S. FDA's Breakthrough Therapy designation for the treatment of certain patients with platinum-resistant ovarian cancer
16 Jan 2026 CNBC Novo Nordisk shares rise 8% after Wegovy obesity pill has 'solid' launch
10 Jan 2026 CNBC 2026 is the year of obesity pills. Here's how they could reshape the GLP-1 market
09 Jan 2026 Pengumuman Vida Ventures Congratulates Aktis Oncology on Its Entry into the Public Markets
09 Jan 2026 CNBC Amazon Pharmacy starts offering Novo Nordisk's Wegovy weight loss pill
08 Jan 2026 Pengumuman Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with active psoriatic arthritis and obesity or overweight
07 Jan 2026 Pengumuman Lilly to acquire Ventyx Biosciences to advance oral therapies targeting inflammatory-mediated diseases
05 Jan 2026 CNBC First GLP-1 pill for obesity from Novo Nordisk launches in the U.S. 
22 Dec 2025 CNBC FDA approves first GLP-1 pill for obesity from Wegovy maker Novo Nordisk
19 Dec 2025 CNBC Nine of the largest pharma companies ink deals with Trump to lower drug prices
18 Dec 2025 CNBC Eli Lilly says obesity pill helps maintain weight loss after patients switch from Wegovy, Zepbound 
18 Dec 2025 Pengumuman Lilly's orforglipron helped people maintain weight loss after switching from injectable incretins to oral GLP-1 therapy in first-of-its-kind Phase 3 trial
16 Dec 2025 Pengumuman Lilly to participate in J.P. Morgan Healthcare Conference
12 Dec 2025 Pengumuman Updated data for Lilly's Inluriyo™ (imlunestrant) reinforce efficacy results as monotherapy and in combination with Verzenio® (abemaciclib) in ER+, HER2- advanced breast cancer
Papar semua
Hasil Dividen (DY TTM) 0.63%
Purata Hasil Dividen 5T 0.78%
Nisbah Pembayaran 43.94%
Tarikh EX Tarikh Pengumuman Tarikh Pembayaran Perincian
14 Feb 2025 09 Dec 2024 10 Mar 2025 1.5 Tunai
15 Nov 2024 28 Oct 2024 10 Dec 2024 1.3 Tunai
15 Aug 2024 24 Jun 2024 10 Sep 2024 1.3 Tunai
15 May 2024 06 May 2024 10 Jun 2024 1.3 Tunai
14 Feb 2024 08 Dec 2023 08 Mar 2024 1.3 Tunai
14 Nov 2023 01 Nov 2023 08 Dec 2023 1.13 Tunai
14 Aug 2023 26 Jun 2023 08 Sep 2023 1.13 Tunai
12 May 2023 01 May 2023 09 Jun 2023 1.13 Tunai
14 Feb 2023 12 Dec 2022 10 Mar 2023 1.13 Tunai
14 Nov 2022 17 Oct 2022 09 Dec 2022 0.98 Tunai
12 Aug 2022 27 Jun 2022 09 Sep 2022 0.98 Tunai
13 May 2022 02 May 2022 10 Jun 2022 0.98 Tunai
14 Feb 2022 13 Dec 2021 10 Mar 2022 0.98 Tunai
12 Nov 2021 18 Oct 2021 10 Dec 2021 0.85 Tunai
12 Aug 2021 29 Jun 2021 10 Sep 2021 0.85 Tunai
13 May 2021 03 May 2021 10 Jun 2021 0.85 Tunai
11 Feb 2021 14 Dec 2020 10 Mar 2021 0.85 Tunai
12 Nov 2020 19 Oct 2020 10 Dec 2020 0.74 Tunai
13 Aug 2020 15 Jul 2020 10 Sep 2020 0.74 Tunai
14 May 2020 04 May 2020 10 Jun 2020 0.74 Tunai
13 Feb 2020 16 Dec 2019 10 Mar 2020 0.74 Tunai
14 Nov 2019 22 Oct 2019 10 Dec 2019 0.645 Tunai
14 Aug 2019 20 Jun 2019 10 Sep 2019 0.645 Tunai
16 May 2019 07 May 2019 10 Jun 2019 0.645 Tunai
14 Feb 2019 19 Dec 2018 08 Mar 2019 0.645 Tunai
14 Nov 2018 16 Oct 2018 10 Dec 2018 0.5625 Tunai
14 Aug 2018 19 Jun 2018 10 Sep 2018 0.5625 Tunai
16 May 2018 07 May 2018 08 Jun 2018 0.5625 Tunai
14 Feb 2018 11 Dec 2017 09 Mar 2018 0.5625 Tunai
14 Nov 2017 16 Oct 2017 08 Dec 2017 0.52 Tunai
11 Aug 2017 19 Jun 2017 08 Sep 2017 0.52 Tunai
11 May 2017 01 May 2017 09 Jun 2017 0.52 Tunai
13 Feb 2017 12 Dec 2016 10 Mar 2017 0.52 Tunai
10 Nov 2016 17 Oct 2016 09 Dec 2016 0.51 Tunai
11 Aug 2016 20 Jun 2016 09 Sep 2016 0.51 Tunai
11 May 2016 02 May 2016 10 Jun 2016 0.51 Tunai
10 Feb 2016 08 Dec 2015 10 Mar 2016 0.51 Tunai
10 Nov 2015 19 Oct 2015 10 Dec 2015 0.5 Tunai
12 Aug 2015 15 Jun 2015 10 Sep 2015 0.5 Tunai
14 May 2015 04 May 2015 10 Jun 2015 0.5 Tunai
11 Feb 2015 15 Dec 2014 10 Mar 2015 0.5 Tunai
12 Nov 2014 20 Oct 2014 10 Dec 2014 0.49 Tunai
13 Aug 2014 16 Jun 2014 10 Sep 2014 0.49 Tunai
13 May 2014 05 May 2014 10 Jun 2014 0.49 Tunai
12 Feb 2014 16 Dec 2013 10 Mar 2014 0.49 Tunai
13 Nov 2013 21 Oct 2013 10 Dec 2013 0.49 Tunai
13 Aug 2013 18 Jun 2013 10 Sep 2013 0.49 Tunai
14 May 2013 03 May 2013 10 Jun 2013 0.49 Tunai
13 Feb 2013 17 Dec 2012 08 Mar 2013 0.49 Tunai
13 Nov 2012 15 Oct 2012 10 Dec 2012 0.49 Tunai
13 Aug 2012 19 Jun 2012 10 Sep 2012 0.49 Tunai
13 Feb 2012 12 Dec 2011 09 Mar 2012 0.49 Tunai
10 Nov 2011 17 Oct 2011 09 Dec 2011 0.49 Tunai
11 Aug 2011 20 Jun 2011 09 Sep 2011 0.49 Tunai
11 May 2011 18 Apr 2011 10 Jun 2011 0.49 Tunai
11 Feb 2011 13 Dec 2010 10 Mar 2011 0.49 Tunai
10 Nov 2010 18 Oct 2010 10 Dec 2010 0.49 Tunai
11 Aug 2010 21 Jun 2010 10 Sep 2010 0.49 Tunai
12 May 2010 19 Apr 2010 10 Jun 2010 0.49 Tunai
10 Feb 2010 14 Dec 2009 10 Mar 2010 0.49 Tunai
10 Nov 2009 19 Oct 2009 10 Dec 2009 0.49 Tunai
12 Aug 2009 22 Jun 2009 10 Sep 2009 0.49 Tunai
13 May 2009 20 Apr 2009 10 Jun 2009 0.49 Tunai
11 Feb 2009 15 Dec 2008 10 Mar 2009 0.49 Tunai
12 Nov 2008 20 Oct 2008 10 Dec 2008 0.47 Tunai
13 Aug 2008 20 Jun 2008 10 Sep 2008 0.47 Tunai
13 Feb 2008 17 Dec 2007 10 Mar 2008 0.47 Tunai
13 Nov 2007 15 Oct 2007 10 Dec 2007 0.425 Tunai
13 Aug 2007 21 Jun 2007 10 Sep 2007 0.425 Tunai
11 May 2007 16 Apr 2007 08 Jun 2007 0.425 Tunai
13 Feb 2007 18 Dec 2006 09 Mar 2007 0.425 Tunai
13 Nov 2006 16 Oct 2006 08 Dec 2006 0.4 Tunai
11 Aug 2006 26 Jun 2006 08 Sep 2006 0.4 Tunai
11 May 2006 24 Apr 2006 09 Jun 2006 0.4 Tunai
13 Feb 2006 19 Dec 2005 10 Mar 2006 0.4 Tunai
10 Nov 2005 17 Oct 2005 09 Dec 2005 0.38 Tunai
11 Aug 2005 24 Jun 2005 09 Sep 2005 0.38 Tunai
11 May 2005 18 Apr 2005 10 Jun 2005 0.38 Tunai
11 Feb 2005 20 Dec 2004 10 Mar 2005 0.38 Tunai
10 Nov 2004 18 Oct 2004 10 Dec 2004 0.355 Tunai
11 Aug 2004 28 Jun 2004 10 Sep 2004 0.355 Tunai
12 May 2004 19 Apr 2004 10 Jun 2004 0.355 Tunai
11 Feb 2004 15 Dec 2003 10 Mar 2004 0.355 Tunai
12 Nov 2003 20 Oct 2003 10 Dec 2003 0.335 Tunai
13 Aug 2003 23 Jun 2003 10 Sep 2003 0.335 Tunai
13 May 2003 28 Apr 2003 10 Jun 2003 0.335 Tunai
12 Feb 2003 16 Dec 2002 10 Mar 2003 0.335 Tunai
13 Nov 2002 21 Oct 2002 10 Dec 2002 0.31 Tunai
13 Aug 2002 24 Jun 2002 10 Sep 2002 0.31 Tunai
13 May 2002 15 Apr 2002 10 Jun 2002 0.31 Tunai
13 Feb 2002 17 Dec 2001 08 Mar 2002 0.31 Tunai
13 Nov 2001 15 Oct 2001 10 Dec 2001 0.28 Tunai
13 Aug 2001 25 Jun 2001 10 Sep 2001 0.28 Tunai
11 May 2001 16 Apr 2001 11 Jun 2001 0.28 Tunai
13 Feb 2001 18 Dec 2000 09 Mar 2001 0.28 Tunai
13 Nov 2000 16 Oct 2000 11 Dec 2000 0.26 Tunai
11 Aug 2000 26 Jun 2000 11 Sep 2000 0.26 Tunai
11 May 2000 17 Apr 2000 09 Jun 2000 0.26 Tunai
11 Feb 2000 20 Dec 1999 10 Mar 2000 0.26 Tunai
10 Nov 1999 18 Oct 1999 10 Dec 1999 0.23 Tunai
11 Aug 1999 19 Jul 1999 10 Sep 1999 0.23 Tunai
12 May 1999 19 Apr 1999 10 Jun 1999 0.23 Tunai
10 Feb 1999 21 Dec 1998 10 Mar 1999 0.23 Tunai
10 Nov 1998 20 Oct 1998 10 Dec 1998 0.2 Tunai
12 Aug 1998 20 Jul 1998 10 Sep 1998 0.2 Tunai
13 May 1998 20 Apr 1998 10 Jun 1998 0.2 Tunai
11 Feb 1998 15 Dec 1997 10 Mar 1998 0.2 Tunai
12 Nov 1997 15 Sep 1997 10 Dec 1997 0.2 Tunai
13 Aug 1997 21 Jul 1997 10 Sep 1997 0.36 Tunai
13 May 1997 21 Apr 1997 10 Jun 1997 0.36 Tunai
12 Feb 1997 16 Dec 1996 10 Mar 1997 0.36 Tunai
13 Nov 1996 21 Oct 1996 10 Dec 1996 0.3425 Tunai
13 Aug 1996 15 Jul 1996 10 Sep 1996 0.3425 Tunai
13 May 1996 15 Apr 1996 10 Jun 1996 0.3425 Tunai
13 Feb 1996 18 Dec 1995 11 Mar 1996 0.3425 Tunai
13 Nov 1995 17 Oct 1995 11 Dec 1995 0.685 Tunai
11 Aug 1995 17 Jul 1995 11 Sep 1995 0.645 Tunai
09 May 1995 17 Apr 1995 12 Jun 1995 0.645 Tunai
Papar semua

Hasil Dividen Tahunan

Tahun Dividen Tahunan ($) Kekerapan/Tahun Hasil %
2025 1.50 1 0.14
2024 5.20 4 0.67
2023 4.52 4 0.78
2022 3.92 4 1.07
2021 3.40 4 1.23
2020 2.96 4 1.75
2019 2.58 4 1.96
2018 2.25 4 1.94
2017 2.08 4 2.46
2016 2.04 4 2.77
2015 2.00 4 2.37
2014 1.96 4 2.84
2013 1.96 4 3.84
2012 1.47 3 2.98
2011 1.96 4 4.72
2010 1.96 4 5.59
2009 1.96 4 5.49
2008 1.41 3 3.50
2007 1.70 4 3.18
2006 1.60 4 3.07
2005 1.52 4 2.69
2004 1.42 4 2.50
2003 1.34 4 1.91
2002 1.24 4 1.95
2001 1.12 4 1.43
2000 1.04 4 1.12
1999 0.920 4 1.38
1998 0.800 4 0.90
1997 1.28 4 1.84
1996 1.37 4 3.75
1995 1.98 3 7.02
Papar semua

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2026 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda